Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With <i>CYP2C19</i> Genetic Variants.

Abstract

Dysglycemia may influence the predictive value of <i>CYP2C19</i> loss-of-function allele for clinical efficacy of antiplatelet drug, but the role of glycated albumin (GA) remains unclear in patients with stroke on antiplatelet drugs. The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) included 2933 patients who had GA levels and <i>CYP2C19</i> genotyping. Cox proportional hazards model was used to assess the interaction between <i>CYP2C19</i> loss-of-function allele (*2, *3) carrier status and the effect of antiplatelet therapy based on their GA levels. There was significant interaction between carrier status and antiplatelet therapy regimen on the risk of recurrent stroke (<i>P</i>=0.03) in patients with GA levels of ≤15.5%, but not in those with GA levels of >15.5% (<i>P</i>=0.48). Only in noncarriers with low GA levels, dual-antiplatelet therapy reduced stroke recurrence (3.5%) compared with those on aspirin alone (14.7%; hazard ratio, 0.23; 95% confidence interval, 0.10-0.49; <i>P</i><0.001). Similar effects were observed when examined the combined vascular event or ischemic stroke. No significant difference in bleeding was found among groups. In patients with minor stroke or high-risk transient ischemic attack, clopidogrel-aspirin when compared with aspirin alone reduced stroke recurrence only in noncarriers of <i>CYP2C19</i> loss-of-function allele and normal GA levels. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.